Radiotracer imaging studies in hepatic encephalopathy: ISHEN practice guidelines

Liver International

Volumn 29, Issue 5, 2009, Pages 621-628

  Berding, Georg ^a   Banati, Richard B ^b   Buchert, Ralph ^c   Chierichetti, Franca ^d   Grover, Vijay P B ^e   Kato, Akinobu ^f   Keiding, Susanne ^g   Taylor Robinson, Simon D ^e  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d PET Centre   (Italy)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f IWATE MEDICAL UNIVERSITY   (Japan)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Animal models; Hepatic encephalopathy; Imaging; Multicentre studies; Positron emission tomography

Indexed keywords

AMMONIA; FLUORODEOXYGLUCOSE F 18; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; PREDNISOLONE; TACROLIMUS; TRACER;

AMMONIA FORMATION; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; DIAGNOSTIC IMAGING; DISEASE MODEL; EVIDENCE BASED MEDICINE; HEPATIC ENCEPHALOPATHY; HUMAN; IMAGE ANALYSIS; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; METHODOLOGY; NERVE CONDUCTION; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AMMONIA; ANIMALS; HEPATIC ENCEPHALOPATHY; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, BIOLOGICAL; MULTICENTER STUDIES AS TOPIC; POSITRON-EMISSION TOMOGRAPHY; RATS;

EID: 64749099248     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02008.x     Document Type: Review

References (43)

1. Jover R, Madaria E, Felipo V, et al. Animal models in the study of epsodic hepatic encephalopathy in cirrhosis. Metab Brain Dis 2005; 20: 399-408.
2. Ytrebø LM, Nedredal GI, Langbakk B, Revhaug A. An experimental large animal model for the assessment of bioartificial liver support systems in fulminant hepatic failure. Scand J Gastroenterol 2002; 37: 1077-88.
3. Chen X, Park R, Khankaldyan V, et al. Longitudinal MicroPET imaging of brain tumor Growth with F-18-labeled RGD peptide. Mol Imaging Biol 2006; 8: 9-15.
4. 13C]raclopride binding in the striatum of the awake cat: effects of anaesthetics and role of cerebral blood flow. Eur J Nucl Med Mol Imaging 2003; 30: 141-8.
5. Hendrich KS, Kochanek PM, Melick JA, et al. Cerebral perfusion during anesthesia with fentanyl, isoflurane, or pentobarbital in normal rats studied by arterial spin-labeled MRI. Magn Reson Med 2001; 46: 202-6.
6. Hildebrandt IJ, Su H, Weber WA. Anesthesia and other considerations for in vivo imaging of small animals. ILAR J 2008; 49: 17-26.
7. Hanusch C, Hoeger S, Beck GC. Anaesthesia of small rodents during magnetic resonance imaging. Methods 2007; 43: 68-78.
8. Ahl B, Weissenborn K, van den Hoff J, et al. Regional differences in cerebral blood flow and cerebral ammonia metabolism in patients with cirrhosis. Hepatology 2004; 40: 73-9.
9. Lockwood AH, McDonald JM, Reiman RE, et al. The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammonemia. J Clin Invest 1979; 63: 449-60.
10. Lockwood AH, Bolomey L, Napoleon F. Blood-brain barrier to ammonia in humans. J Cereb Blood Flow Metab 1984; 4: 516-22.
11. Lockwood AH, Yap EW, Wong WH. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991; 11: 337-41.
12. 13 N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography. Hepatology 2006; 43: 42-50.
13. Slifstein M, Frankle WG, Laruelle M. Ligand tracer kinetics: Theory and application. In: Otte A, Audenaert K, Peremans K, van Heeringen K, Dierckx RA, eds. Nuclear Medicine in Psychiatry. Berlin Heidelberg: Springer, 2004; 75-93.
14. Ott P, Larsen FS. Blood-brain barrier permeability to ammonia in liver failure: A critical reappraisal. Neurochem Int 2004; 44: 185-98.
15. Crone C. The permeability of capillaries in various organs as determined by use of the 'indicator diffusion' method. Acta Physiol Scand 1963; 58: 292-305.
16. Renkin EM. Transport of potassium-42 from blood to tissue in isolated mammalian skeletal muscles. Am J Physiol 1959; 197: 1205-10.
17. 13N-ammonia PET. Metab Brain Dis 2007; 22: 277-84.
18. van den Hoff J, Burchert W, Muller-Schauenburg W, Meyer GJ, Hundeshagen H. Accurate local blood flow measurements with dynamic PET: Fast determination of input function delay and dispersion by multilinear minimization. J Nucl Med 1993; 34: 1770-7.
19. 15O and positron emission tomography. J Cereb Blood Flow Metab 1987; 7: 421-6.
20. 13N-labeled ammonia in rat brain. J Biol Chem 1979; 254: 4982-92.
21. 13N]ammonia in human and canine blood. J Nucl Med 1990; 31: 163-7.
22. Lockwood AH, Wack DS. The brain permeability-surface product for ammonia. Hepatology 2006; 44: 1052-3.
23. Von Schulthess G., (ed.) Clinical Molecular Anatomic Imaging: PET, PET/ CT, and SPECT/CT. Philadelphia, USA: Lippincott Williams and Wilkins, 2003.
24. Townsend DW. Multimodality imaging of structure and function. Phys Med Biol 2008; 53: R1-39.
25. Pichler BJ, Judenhofer MS, Wehrl HF. PET/MRI hybrid imaging: Devices and initial results. Eur Radiol 2008; 18: 1077-86.
26. Grover VP, Dresner MA, Forton DM, et al. Current and future applications of magnetic resonance imaging and spectroscopy of the brain in hepatic encephalopathy. World J Gastroenterol 2006; 12: 2969-78.
27. Patel N, Forton DM, Coutts GA, Thomas HC, Taylor-Robinson SD. Intracellular pH measurements of the whole head and the basal ganglia in chronic liver disease: A phosphorus-31 MR spectroscopy study. Metab Brain Dis 2000; 15: 223-40.
28. Jalan R, Turjanski N, Taylor-Robinson SD, et al. Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis. Gut 2000; 46: 546-52.
29. Lozeva-Thomas V. Serotonin brain circuits with a focus on hepatic encephalopathy. Metab Brain Dis 2004; 19: 413-20.
30. Weissenborn K, Berding G, Köstler H. Altered striatal dopamine D2 receptor density and dopamine transport in a patient with hepatic encephalopathy. Metab Brain Dis 2000; 15: 173-8.
31. Weissenborn K, Bokemeyer M, Ahl B, et al. Functional imaging of the brain in patients with liver cirrhosis. Metab Brain Dis 2004; 19: 269-80.
32. Cagnin A, Taylor-Robinson SD, Forton DM, Banati RB. In vivo imaging of cerebral "peripheral benzodiazepine binding sites" in patients with hepatic encephalopathy. Gut 2006; 55: 547-53.
33. Desjardins P, Butterworth RF. The "peripheral-type" benzodiazepine (omega 3) receptor in hyperammonemic disorders. Neurochem Int 2002; 41: 109-14.
34. Iversen P, Hansen DA, Bender D, et al. Peripheral benzodiazepine receptors in the brain of cirrhosis patients with manifest hepatic encephalopathy. Eur J Nucl Med Mol Imaging 2006; 33: 810-6.
35. Mullen KD, Amodio P, Morgan MY. Therapeutic studies in hepatic encephalopathy. Metab Brain Dis 2007; 22: 407-23.
36. Kato A, Suzuki K, Kaneta H, et al. Regional differences in cerebral glucose metabolism in cirrhotic patients with subclinical hepatic encephalopathy using positron emission tomography. Hepatol Res 2000; 17: 237-45.
37. Iversen P, Sørensen M, Bak LK, et al. Low cerebral oxygen consumption and blood flow in patients with cirrhosis and an acute episode of hepatic encephalopathy. Gastroenterology 2009; 136: 863-71.
38. Zhang LJ, Yang G, Yin J, Liu Y, Qi J. Neural mechanism of cognitive control impairment in patients with hepatic cirrhosis: A functional magnetic resonance imaging study. Acta Radiol 2007; 48: 577-87.
39. Grover VP, Pavese N, Koh S-B, et al. Evidence of neuroinflammation in patients with chronic hepatitis C: A cerebral positron emission tomography (PET) study. J. Hepatol 2008; 48 (Suppl. 2): S275.
40. Neeb H, Zilles K, Shah NJ. A new method for fast quantitative mapping of absolute water content in vivo. Neuroimage 2006; 31: 1156-68.
41. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. Br Med J 2008; 336: 1049-51.
42. Guyatt GH, Oxman AD, Kunz R, et al. Incorporating considerations of resources use into grading recommendations. Br Med J 2008; 336: 1170-3.
43. Guyatt GH, Oxman AD, Kunz R, et al. What is "quality of evidence"and why is it important to clinicians? Br Med J 2008; 336: 995-8.